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As directors of two NIH institutes supporting neuroscience research, we explore the gap between 25 years of
stunning progress in fundamental neuroscience and the persistent needs of those with brain disorders. We
conclude that closing this gap will require a more detailed comprehension of brain function, a rethinking of
how we approach translational science, a focus on human neurobiology, and a continuing commitment to
build a diverse, innovative neuroscience workforce. In contrast to many other areas of medicine, we lack
basic knowledge about our organ of interest. The next phase of progress on brain disorders will require a
significantly deeper understanding of fundamental neurobiology.InMarch 1988, the editors ZachHall, A.J. Hudspeth, Eric Kandel,
and Louis Reichardt launched the first issue of Neuron, ‘‘based
on the belief that cellular and molecular neurobiology has begun
a period of explosive growth, fueled by the powerful experi-
mental tools that have recently become available’’ (Hall et al.,
1988). What were the new tools of 1988? They cite recombinant
DNA methods, new electrophysiological recording techniques
(e.g., patch clamping), novel methods of introducing macromol-
ecules into cells (e.g., viral transfection), and new approaches to
cellular imaging (e.g., confocal imaging). Along with their enthu-
siasm for recent technical advances for molecular and cellular
neurobiology, they commit the journal to the latest technology
for rapid publication: ‘‘To minimize the time delays caused by
distance, we shall use express mail and facsimile transmission
for manuscripts from abroad.’’
In the 25 years since, the information revolution has obviously
transformed the speed of communication and publishing: man-
uscripts move via email, and publications can appear a month
or more before the journal is printed. But the changes in cellular
and molecular neurobiology are as profound. At each level, from
molecular, to cellular, to systems neuroscience, technical break-
throughs have led to conceptual progress. We are, in 2013, no
less than in 1988, in a ‘‘period of explosive growth.’’ Others in
this special issue of Neuron have captured the many facets of
this growth. Below we highlight a few of these areas, recognizing
that this brief survey cannot do justice to either the technical or
the conceptual advances of the past 25 years. Our charge is to
relate these changes to the state of brain disorders in 2013, iden-
tifying the best bridges for translational research. We conclude
that progress on brain disorders will require a significantly
deeper understanding of fundamental neurobiology.
What Has Happened since 1988?
Molecular Neuroscience
The genomic revolution has not only revealed the genomic
sequences of over 150 eukaryotic species but also spawned
new, inexpensive technologies that have moved high-throughput sequencing from a few centers to hundreds of
benchtops. One unforeseen consequence of the genomic revo-
lution and its high-throughput methods has been the generation
of a whole family of ‘‘omics,’’ where ‘‘omics’’ denotes compre-
hensive, unbiased approaches or disciplines that begin with
the word ‘‘all.’’ We now have epigenomics identifying ‘‘all the
epigenetic marks,’’ transcriptomics identifying ‘‘all the tran-
scripts,’’ proteomics identifying ‘‘all the proteins,’’ and metabo-
lomics identifying ‘‘all the metabolites,’’ to name just a few.While
we have been concerned about the potential dominance of ‘‘big
science’’ over the past two decades, we are now seeing that
many of the tools and resources developed by large, centralized
efforts like the Human Genome Project have effectively enabled
innovative, investigator-initiated research. For instance, the
millionfold drop in the cost of sequencing over the past decade
has allowed hundreds of labs to do molecular biology on a scale
once reserved for a few well-funded centers.
As a result of these new tools and comprehensive ap-
proaches, we are now in an extraordinary era of discovery
science. The few hundred genes, proteins, and metabolites
that appeared relevant in 1988 have been expanded with the
recognition that over 80% of our approximately 20,000 genes
are expressed in the human brain (Hawrylycz et al., 2012) and
that many of these are expressed as unique isoforms in the brain,
often in developmentally and spatially restricted patterns (Colan-
tuoni et al., 2011; http://www.BrainSpan.org). Until recently, our
focus in the genome has been on the 1.5% of the sequence that
codes for protein. With the recent recognition that over 80% of
the genome is transcribed, we are beginning to appreciate
how the genome codes for many different species of RNA and
other elements that are essential for the regulation of gene
expression (Bernstein et al., 2012; Yates et al., 2013; Batista
and Chang, 2013). In addition, we are discovering epigenetic
processes for the regulation of gene regulation that appear to
be unique to the brain (Lister et al., 2013), providing a potential
mechanism for environmental influences on molecular, cellular,
and systems-level processes.Neuron 80, October 30, 2013 ª2013 Elsevier Inc. 561
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over the past two decades has been accelerated by tools to
manipulate the genome. In addition to describing a vast new
universe of genes and molecules, we have the tools to test
specificmechanisms. Over 1,200 transgenic mutant mouse lines
have been produced and phenotyped. The advent of conditional
knockouts and specific recombinases has made it possible to
create mice to test the role of genes in specific cells and at
specific developmental times. New, precise tools for manipu-
lating genomic sequence and gene expression, such as
TALENS, CRISPR, and LITE (Gaj et al., 2013; Konermann
et al., 2013), are yielding even more powerful experimental tech-
niques to link genes to function.
Cellular Neuroscience
A parallel revolution in cell biology has been equally transfor-
mative. In 1988, our picture of cellular neuroanatomy and func-
tion was much simpler than it is today. The development of
various fluorophores, yielding elegant anatomical maps like
Brainbow, and two-photon imaging, yielding in vivo pictures
of spine formation, has given us a far more detailed under-
standing of the variety of cells in the brain and their complexity.
CLARITY has provided a novel technique for three-dimensional
neuroanatomy (Chung et al., 2013). While we still lack a
comprehensive taxonomy of brain cell types (Wichterle et al.,
2013), we have a better understanding of how cells develop,
migrate, and communicate. Improved lineage tracking (clonal
analysis) techniques have helped elucidate how neural stem
cells give rise to daughter neurons, astrocytes, and oligoden-
drocytes, and uncovered an unexpected glia-like property of
neural stem cells. Tools to report and manipulate the function
of genes in specific cell types have revealed the complex inter-
action of guidance cues among neurons and the vital role of
glia in synaptic maturation, elimination, and plasticity. We
now realize that neurogenesis continues in selected popula-
tions (even in human brain) and that adult-born neurons
contribute to cognitive function (Denny et al., 2012; Sahay
et al., 2011).
The emergence of new cell reprogramming techniques
yielding induced pluripotent stem (iPS) cells in vitro from adult
fibroblasts would have been dismissed as science fiction in
1988. This technique allows human cellular and developmental
processes to be modeled (Zhu and Huangfu, 2013); it has
already begun to provide a new window into the role of common
and rare mutations associated with neuropsychiatric disorders
(Krey et al., 2013) and a new platform for screening potential
therapies. Additionally, it is providing a source of patient-
matched neurons that may be useful for cell therapies for neuro-
degenerative disorders such as Parkinson’s disease.
Much of the cellular neurobiology of 1988 was focused on
membrane currents, ion channels, or receptors. We now have
the molecular structures of an increasing number of these
membrane components, elucidating the biophysical machines
responsible for neuronal activity. At the same time, emerging
technologies now allow molecular analysis of single cells within
a population, uncovering subtle differences that may explain
phenotypic cell diversity. Such resolution will be critical in corre-
lating molecular changes with other functional parameters
among many neurons in a network.562 Neuron 80, October 30, 2013 ª2013 Elsevier Inc.Systems Neuroscience
Arguably the greatest progress has been in the study of brain cir-
cuits, from C. elegans, where the entire nervous system can be
monitored, to humans, where fMRI and structural imaging have
given us new insights into brain organization and function. Much
of the physiology of the last 25 years has shifted from a focus on
the single channel or single cell to ensembles or circuits, in search
of patterns of activity that link to behavior. Recording has been
expanded to ensembles of neurons, and calcium-imaging dyes
or voltage-sensitive dyes are now used to monitor the activity of
hundreds of neurons over time to begin tomap how andwhere in-
formation is processed. Most recently, the capture of simulta-
neous, real-time activity of over 80% of the neurons in the larval
zebrafish brain with lightsheet microscopy suggests patterns of
large-scale activity that had not been foreseen by recording indi-
vidual or even small groups of neurons (Ahrens et al., 2013).
The macroconnectome now being developed promises to
provide a reference atlas of the wiring diagram of the human
brain, much as the genome project provided a reference atlas
of DNA sequence (http://www.humanconnectome.org). Beyond
better descriptions of connections and circuitry, tools like opto-
genetics (Tye and Deisseroth, 2012) and DREADDs (Nawaratne
et al., 2008) have provided neuroscientists with the ability to
manipulate sets of cells in circuits to test specific causal ques-
tions about circuit and network anatomy, connectivity, and func-
tion. Who could have imagined in 1988 the broad use of tools,
based on advances in molecular and cellular neuroscience, for
precise control over circuits in awake, behaving animals?
As a result, we can now begin to understand ongoing activity
patterns that are overlaid on anatomical structure and to study
how experience alters circuit function. For some invertebrate
circuits, the entire network has been specified and elegantly
modeled (Bargmann and Marder, 2013). These studies make
clear that although form and function are related, knowing the
microanatomy of connections is not sufficient to understand
the function of a simple circuit. We are just beginning to under-
stand the principles of brain organization that are essential for
information encoding, storage, manipulation, and retrieval.
Indeed, understanding the stages and processes of manipula-
tion of information within neural networks will be the next major
challenge for neuroscience.
What Has Not Happened since 1988?
The extraordinary progress in neuroscience over the past two
decades may, in retrospect, look like the unprecedented two-
decade period in physics just a century ago. New tools and
new concepts have transformed the way we think about the
brain and its constituent parts, a transformation that has been
chronicled faithfully in Neuron, monthly beginning in 1988 and
bimonthly beginning in 2001, as the journal, responding to the
evolution of the field, expanded its scope beyond the original
mandate of molecular and cellular neuroscience. What about
progress in clinical research and clinical care? Has the transfor-
mation in basic neuroscience meant transformed outcomes for
people with brain disorders?
Burden of Disease
The inconvenient truth in 2013 is that neuropsychiatric disorders
represent the leading source of disease burden in the developed
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Over the past 25 years, success against acute infectious dis-
eases and infant mortality has left chronic, noncommunicable
diseases as the largest source of disability. In contrast to heart
disease or most forms of cancer, many neuropsychiatric disor-
ders (e.g., autism, epilepsy, schizophrenia, intellectual disability)
begin early in life and contribute to lifelong disability or reduced
longevity. Indeed, these disorders are now the chronic diseases
of the young and globally have become the largest source of
years lived with disability (Whiteford et al., 2013). At the same
time, neurodegenerative disorders have increasingly become
the signature disabilities of an aging population. Changing de-
mographics ensure that brain disorders will be a greater public
health challenge in the coming decades.
The public health challenge is mortality as well as morbidity.
Many brain disorders are fatal. Stroke is the fourth leading cause
of death in the United States and second globally. Death occurs
within 5 years of a diagnosis of amyotrophic lateral sclerosis
(ALS), 10 years after symptoms of Alzheimer’s disease, and
twenty after symptoms of Huntington’s disease. The risk of
sudden unexplained death in epilepsy is 24 times greater than
that in the general population (Neligan et al., 2011). For serious
mental illnesses, like schizophrenia and bipolar disorder, suicide
is common. Indeed, most suicides involve amental disorder, and
there are now over 38,000 suicides in the United States, more
than twice the number of homicides and more than the number
of motor vehicle fatalities (CDC, 2013). It has been reported
that, in the United States, people with serious mental illness
die at least 8 years earlier than those without these illnesses
(Druss andWalker, 2011). Suicide accounts for only a small frac-
tion of this early mortality, most of which results from chronic
medical conditions that are poorly treated in this population.
Perhaps it should not be surprising, given the high morbidity
and mortality, that the cost of neuropsychiatric disorders trumps
other chronic, noncommunicable disorders. In a World Eco-
nomic Forum study of projected costs, neuropsychiatric disor-
ders were estimated to be the most costly, accounting for
more than cancer, diabetes, and chronic respiratory diseases
combined (Bloom et al., 2011). For Alzheimer’s disease alone,
costs of care in the United States in 2010 have been estimated
as between $157 billion and $225 billion (Hurd et al., 2013),
with projections of costs surpassing $1 trillion in 2050.
These sobering statistics about brain disorders stand in stark
contrast to the progress in neurobiology. Why the gap? Why has
25 years of ‘‘explosive growth’’ in neurobiology failed to reduce
the morbidity or mortality of virtually all brain disorders? One
explanation is that our basic science is misguided, not relevant
to clinical problems. Another explanation, which we favor, is
that we do not know enough yet to translate basic neurobiology
into the new diagnostics and therapeutics that will transform
public health outcomes. Let’s look at both of these possibilities.
Relevance of Basic Science to Clinical Care
Although clinical progress is usually measured in breakthrough
therapies, progress in improving diagnostics, elucidating
disease pathogenesis, and generating biomarkers can be as
important and may be a prerequisite for better treatments. Since
1988, there has been considerable scientific progress on brain
disorders.In the past 25 years, genetic mutations underlying a myriad of
inherited neurologic disorders have been identified. These
discoveries now enable rapid and accurate diagnosis, reducing
or even eliminating the diagnostic odyssey, and in some cases
even allow for presymptomatic diagnosis. Whole-exome
sequencing of families with affected individuals promises to
uncover genetic causes of scores of diseases and already has
identified de novo mutations for a number of the childhood epi-
lepsies (Allen et al., 2013). For neurodegenerative disorders, rare
disease-causing mutations in common conditions such as
Alzheimer’s disease (APP, presenilin) and Parkinson’s disease
(synuclein, Parkin, Pink1, LRRK2) and rare diseases like ALS
(superoxide dismutase, C9orf72) are shedding light on causative
molecular pathways (Bertram and Tanzi, 2005). These pathways
in turn may lead to ‘‘druggable targets’’ for potential disease-
modifying therapy. In the near term, projects like the Alzheimer’s
Disease Neuroimaging Initiative are yielding biomarkers to track
disease progression in patients. For Alzheimer’s disease, it is
possible to image sentinel molecules, like tau- and b-amyloid,
and to measure them in cerebrospinal fluid, as well as track hip-
pocampal atrophy (Toledo et al., 2013). Similar efforts are
underway in Parkinson’s disease. The impact of these kinds of
biomarkers can be seen in multiple sclerosis, where the preven-
tion of gadolinium-enhancing MRI lesions has accelerated the
development of treatments (Bermel et al., 2013).
While we still lack biomarkers for mental disorders, the tools of
basic science are now beginning to change how we approach
diagnosis. The discovery of shared genetics, often implicating
genes critical for brain development, has supported a new formu-
lation of mental disorders as neurodevelopmental disorders
(Smoller et al., 2013). With functional MR and PET imaging, spe-
cific circuits have been implicated in depression, obsessive-
compulsive disorder, and posttraumatic stress disorder (Insel,
2010). A new approach to classification of psychiatric disorders,
called the Research Domain Criteria (RDoC) project, is based on
cognitive domains and circuitry (Cuthbert and Insel, 2013). RDoC
attempts to transform diagnosis by building on the findings of
neuroscience and cognitive science, rather than relying solely
on presenting symptoms, as done for the past century. This
approach presumes that what we now call ‘‘depression’’ or
‘‘schizophrenia’’ are, in fact,manydifferent disorderswithdistinct
underlying biological causes that require different treatments.
While this approach is not ready for clinical use, it demonstrates
the extent to which mental disorders are now addressed as brain
disorders, or, more specifically, as brain circuit disorders.
Across brain disorders, whether primarily neurologic or
psychiatric, there is an increasing recognition that behavioral
symptoms are late manifestations of disease. This insight for
Alzheimer’s, Parkinson’s, schizophrenia, and autism represents
a fundamental shift in emphasis, similar to the shift in the treat-
ment of atherosclerosis and hypertension before they cause
ischemic heart disease or stroke. This preemptive approach
focuses on early detection of brain changes and the develop-
ment of early interventions that can prevent or forestall neurode-
generative or neurodevelopmental disorders.
Therapeutics
What about new treatments? Basic science has yielded several
new molecular targets that have become the basis of newNeuron 80, October 30, 2013 ª2013 Elsevier Inc. 563
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have brought breakthroughs in the treatment of migraine (trip-
tans; Lipton, 2011), multiple sclerosis (beta interferon, copol-
ymer, fingolimide, and difumarate; Stankiewicz et al., 2013),
acute stroke (tissue plasminogen activator), and a number of
new agents for epilepsy, including rapamycin for epilepsy in
tuberous sclerosis (Krueger et al., 2013). For mental disorders,
we have seen the development of second-generation antipsy-
chotics and antidepressants, with different side effect profiles
but little improvement in efficacy over the medications of 1988.
There have been few novel targets in this space, in part because
of the limited understanding of the pathophysiology of neurode-
velopmental disorders, relative to the progress on neurodegen-
erative diseases (Hyman, 2012). One hopeful discovery is the
relatively recent insight that antidepressant effects can be
achieved within hours rather than weeks (Martinowich et al.,
2013). The observation that ketamine resolves even treatment-
refractory depression in less than 24 hr has changed our expec-
tations for the development of new antidepressants.
Basic science has also yielded insights about circuitry that
have been translated into new, effective therapies. Modulation
of circuits through deep brain stimulation (DBS) has proven
to be effective for movement disorders including Parkinson’s
disease, essential tremor, and dystonia (Miocinovic et al.,
2013). Development of DBS surgery for Parkinson’s disease
resulted from decades of basic science studies of basal ganglia
circuitry in nonhuman primates (DeLong and Wichmann, 2007).
More recently, DBS in the subcallosal cingulate region, identi-
fied as metabolically hyperactive in patients with severe drug-
resistant depression, showed dramatic antidepressant effects
(Holtzheimer et al., 2012). Epilepsy, a classic neural circuit
disorder, is treated continuously with levels of drugs that
have a wide range of unwanted CNS side effects. Yet the
epileptic discharges are paroxysmal, and seizures occur inter-
mittently in most patients. An accurate detection of preseizure
neural activity might lead to more beneficial delivery of drug
therapy or even direct brain stimulation to abort seizures with
greater efficacy and less adverse side effects (Stacey and
Litt, 2008).
In 1988, treatments in psychiatry were largely divided between
psychotherapy and pharmacotherapy. While it would be naive to
suggest that this division no longer exists, cognitive neurosci-
ence in the past decade has begun to put psychotherapy into
the context of neural plasticity, with studies of how the brain
changes during psychotherapy and the development of cogni-
tive therapies based specifically on feedback from fMRI signals
(Linden et al., 2012).
In sum, our basic science has not been misdirected—it is
unfinished. In 2013, basic science insights have begun to inform
diagnostics and therapeutics, but we are still at the very begin-
ning of an unpredictable journey. We simply do not know enough
yet to solve the very complex problems of brain disorders. In
contrast to cardiology, nephrology, and pulmonary medicine,
we know comparatively little about the organ involved in neuro-
psychiatric disease. To ensure that the next 25 years closes this
gap between basic science and clinical need, we must over-
come four critical barriers. In the remainder of this essay we
explain each of these.564 Neuron 80, October 30, 2013 ª2013 Elsevier Inc.What Do We Need in 2013?
Basic Science
Our biggest barrier is simply that we need a deeper understand-
ing of how the brain works if we are to understand brain disor-
ders. We still do not have the fundamentals. How do different
cell types develop? What roles do glial and immune cells play
in development, homeostasis, and neurodegeneration? How
do cells form circuits? How do circuits encode information?
How does the brain support mental life? For some disorders
(e.g., ALS and epilepsy), single-cell biology may bring the critical
insights. For others (e.g., schizophrenia and autism), under-
standing the development of circuits will likely be essential. Neu-
rodevelopmental disorders may pose even greater challenges
than neurodegenerative disorders, especially when the critical
changes are prenatal. While we are acutely aware of the urgency
of translation, we believe that the translational bridge must be
built on a solid footing in fundamental neuroscience.
This deeper understanding requires better tools. The theoret-
ical physicist Freeman Dyson famously noted that ‘‘new direc-
tions in science are launched by new tools much more often
than by new concepts’’ (Dyson, 1997). We agree. The BRAIN
Initiative is a new commitment to create the tools for understand-
ing the ‘‘language of the brain.’’ We are just at the beginning of
this initiative, but if recent progress in molecular and cellular
technology is a prologue, we can expect rapid progress. Specif-
ically, we will need tools for more precise monitoring and manip-
ulation of brain function over time in awake, behaving animals.
Rethinking Translation
The recent history of progress in other areas ofmedicine reminds
us that transformative clinical applications can arise from basic
science that is not targeting a specific disease or clinical need.
This will be equally true in neuroscience, as demonstrated by
studies of synaptic plasticity that have unexpectedly led to a
new therapeutic approach to fragile X syndrome (Michalon
et al., 2012). Indeed, given the fundamental role of nervous
system plasticity across domains of function and the lifespan,
it is clearly a key focus for unraveling the causes of neuropsychi-
atric disorders and developing targeted and effective pre-emp-
tive interventions, well beyond the example of fragile X. We
have made great strides in understanding how plasticity is regu-
lated by biophysical and epigenetic mechanisms within cell
compartments, across cell types, and across circuits, but there
are significant gaps that prevent the application of basic neuro-
science insights to clinical application.
As NIH institute directors, we have a growing concern about
the tendency for every basic science grant application to
mention a disease or to defend its translational impact. These
‘‘translational blurbs,’’ which seem increasingly to be essential
for some reviewers to assign a fundable score, are rarely sub-
stantive, may be misleading, and fail to recognize the large gap
that remains between the state of our basic understanding and
what is required for clinical application.
Simply put, this gap requires more fundamental neurobiology.
This gap will not be bridged by superficial associations between
basic science and human disease or by assuming that trans-
genic mice are phenocopies of human disease. It has become
abundantly clear that so-called ‘‘disease models’’ fall short
when it comes to developing treatments and cures for human
Neuron
Perspectivedisorders. But the problems with ‘‘animal models’’ do not inval-
idate the use of ‘‘model animals’’ (Insel, 2007). The value of using
model systems is that we can learn about fundamental principles
of brain organization. While most scientists think of translation as
moving from bench to bedside or mouse to man, the future may
belong more to reverse translation, moving from an observation
in humans to experiments in a nonhuman species that can
provide insights into fundamental mechanisms that are similar
to or informatively different from humans. Studying the nervous
system in model animals not only gives us insight into basic
mechanisms but also helps us understand what makes us
uniquely human.
Human Neurobiology
In considering what we need in 2013, one area that deserves
special mention is human neurobiology. Human neurophysi-
ology has begun to inform neuroprosthetics (Chadwick et al.,
2011) and new interventions for epilepsy (Smart et al., 2012).
Invasive techniques such as DBS and noninvasive techniques,
such as regional transcranial magnetic stimulation (rTMS), are
being used to explore brain activity as well as for treating brain
disorders (Demirtas-Tatlidede et al., 2013). Tools for imaging
hemodynamic or metabolic signals in the human brain during
tasks or at rest have given us a rich literature, extending from
anatomy to economics. But we need to be mindful of the limita-
tions of these tools. The fastest hemodynamic signals occur over
seconds, at least two orders of magnitude slower than the speed
of information processing in the brain. Imaging with the highest
spatial resolution, currently a voxel of about 1 cubic mm
isotropic, has been estimated to contain 80,000 neurons and
4.5 million synapses. Moreover, these techniques are cross-
sectional, yielding a picture of blood flow or metabolism at a
point in time. Relative to the tools we have for experimental an-
imals, including not only longitudinal in vivo cellular resolution im-
aging but also manipulations such as optogenetics, our toolkit
for human neurobiology remains primitive. This is especially un-
fortunate because so many of the important questions linking
brain and mind involve functions that may be unique to humans.
Human Capital
One of themost important needs is not a tool or a technique but a
workforce. As directors of two of the major neuroscience insti-
tutes at NIH, we think a lot about the workforce. Although our
budgets have increased more than 3-fold since 1988, funding
has been cyclical and, recently, mostly flat or decreasing.
Indeed, over the past decade we have watched our purchasing
power decline by over 20% (Wadman, 2012). The tightening of
the NIH budget, sometimes called the ‘‘undoubling,’’ has led to
falling paylines and intense competition for research support. It
has also raised important questions about training. How can
we balance the workforce pipeline and the research payline?
Who should be in the pipeline?What skills will future neuroscien-
tists need? We have two general answers to these questions.
First, we will continue to need outstanding new and estab-
lished investigators whowant to explore the vast areas of molec-
ular, cellular, and systems neuroscience that, despite having
been revealed by the ‘‘omics,’’ remain largely frontier territory.
Even in tight funding times, indeed especially in tight funding
times, we are committed to supporting curious, rigorous investi-
gators who are not following the crowd. Scientists with back-grounds in engineering, computation, nanotechnology, and a
range of other disciplines may be especially suited to colonizing
the many frontiers of neuroscience in this next decade.
A second workforce issue for both NINDS and NIMH is the
clinical or translational workforce. We have long marveled how
neurology and psychiatry are two disciplines separated by a
common organ. Recent discoveries from genomics and imaging
as well as the apparent ‘‘comorbidities’’ across brain disorders
(e.g., depression in Parkinson’s and epilepsy in autism) remind
us that the separation of neurology and psychiatry is based
more on history than biology. Once a single discipline before
psychoanalysis split neurology and psychiatry, the modern
view of both neurological and mental disorders as brain disor-
ders dictates a remarriage, rebranded as ‘‘clinical neuroscience’’
(Insel and Quirion, 2005). Joint training would be a good place to
begin, with all clinical neuroscientists exposed to modern neuro-
science as the core of their training.
Final Thoughts
The past 25 years have seen spectacular progress, but much of
this has yet to change the lives of millions struggling with CNS
disorders, from autism to Alzheimer’s disease. The urgency of
this need dictates we do better. Many have argued that ‘‘better’’
means ‘‘faster’’ translation—the need tomovemore quickly from
the bench to the bedside. We agree that time matters and the
needs are urgent. Unfortunately, for most clinical problems, we
still do not have the fundamental knowledge to translate. Moving
from genomics to biology, from cells to circuits, from mice to
people, has proven more far more challenging than expected.
We need a deeper understanding of the basic biology of how
the brain works in both health and disease. This understanding
will require better tools, more basic science, more human neuro-
biology, and a continued commitment to a diverse workforce
funded for innovation.
As with many areas of science, neuroscience in the United
States in 2013 faces a precarious future. Today, while the oppor-
tunities for progress have never beenmore obvious, the certainty
of funding to support rapid progress is not. The President’s
BRAIN Initiative, scheduled for 2014, includes a commitment
for new funding for neuroscience, especially for new tool devel-
opment. If this funding is appropriated by Congress, we are
hopeful that what the President has called ‘‘the next great Amer-
ican project’’ will launch a new investment in neuroscience. But it
is important to put this in context. Biomedical research in the
United States has traditionally been supported heavily by indus-
try. Indeed, the research and development investment from
pharmaceutical and biotech companies of roughly $50 billion
easily surpasses the NIH budget of roughly $30 billion. In 2013,
neuroscience in the United States faces double jeopardy: in
addition to the sequester-driven cuts to NIH funding, many phar-
maceutical companies have reduced their commitments to
research on brain disorders. Thankfully, several foundations
have arisen that are committed to supporting neuroscience
research directly. The Simons Foundation Autism Research
Initiative, the Michael J. Fox Foundation for Parkinson’s
Research, and the CHDI Foundation are just a few of the organi-
zations that are making a difference by funding relevant basic
science as well as clinical research. At the Janelia FarmNeuron 80, October 30, 2013 ª2013 Elsevier Inc. 565
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established a program to map the structure and function of
neural circuits, including optimization of tools like GCaMP.
Perhaps there is no more remarkable example of how the
support of science has changed since 1988 than the Allen Insti-
tute for Brain Science. Who would have imagined a neurosci-
ence research institute funded with over $500 million of private
money (roughly the NIMH or NINDS budget of 1988) would
provide the field with public atlases of the mouse, monkey,
and human brains, as well as map the mouse visual system?
For the generation just entering our field, this must seem like
scientifically the best of times and financially the worst of times.
Those of us who have been in neuroscience for decades have
seen tough times before. But we have never seen a period of
such promise for innovation and discovery. We are committed
to ensuring that the best science continues to be supported,
especially the fundamental science that will ultimately lead to
the breakthrough diagnostics and therapeutics so urgently
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